- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Study: Higher levels of sleep aid melatonin may reduce prostate cancer risk
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
- Appropriations bill to boost funding for Lupus Research Institute's education program
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
DEERFIELD, Ill. — Takeda Pharmaceutical has launched a drug for treating high blood pressure in adults, the company said.
Takeda announced the availability of Edarbyclor (azilsartan medoxomil and chlorthalidone), a once-daily tablet for the condition, also known as hypertension.
"February is American Hearth Month, and it's important to recognize that nearly 40% of hypertension patients are not at their blood pressure targets, putting them at increased cardiovascular risk," Takeda Pharmaceuticals U.S.A. president Douglas Cole said. "We're pleased to bring Edarbyclor to market and expand the Edarbi family of products to help appropriate patients with hypertension work towards reaching their blood pressure goals."